Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zynlonta
Pharma
Patient deaths raise questions about ADC's cancer drug Zynlonta
Three times as many deaths in the study arm vs. the control arm in a trial of ADC's Zynlonta have raised questions about the antibody-drug conjugate.
Kevin Dunleavy
Jun 4, 2026 11:38am
ADC touts early Zynlonta results in marginal zone lymphoma
May 6, 2024 4:19pm
ADC Therapeutics scraps Zynlonta study after FDA partial hold
Jul 21, 2023 11:13am
ADC pauses Zynlonta study after 7 patient deaths
Jul 11, 2023 12:23pm
ADC Therapeutics taps Sobi to market Zynlonta outside of US
Jul 8, 2022 10:55am
David Gilman joins Ameet Mallik on ADC Therapeutics' exec board
Jun 14, 2022 3:57pm
